ANDA 201361, held by Perrigo R&D. Omeprazole; Sodium Bicarbonate.
As of Nov 21, 2026, ANDA 201361 (Omeprazole and Sodium Bicarbonate), held by Perrigo R&D, was first approved by FDA on Jul 15, 2016, with 4 approved supplements and 0 published complete response letters.
Use
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Omeprazole and Sodium Bicarbonate20MG;1.1GM · capsule;oral | Omeprazole; Sodium Bicarbonate | OTC |
| Feb 5, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 5, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 5, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Feb 5, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 15, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters